HYTN Secures Cannabis Drug Licence, Advancing Prescription Drug Pathway for Cannabinoid-Based Medicines - Seite 2

Despite these advancements, access to GMP-compliant, cannabis-derived APIs and finished drug products remains limited, due in part to the high regulatory and operational standards required to serve the pharmaceutical supply chain.

With the recent issuance of its CDL, HYTN joins a small group of global manufacturers equipped to support:

• Clinical-stage pharmaceutical sponsors and biotech companies seeking GMP cannabinoid inputs.
• Distributors and pharmacies in Europe, the UK, and Australia operating under prescription-only frameworks.
• Special access, named patient, and compassionate use programs requiring pharmaceutical-grade supply.
• Government tenders and public health initiatives focused on regulated cannabinoid therapies.

This expanded regulatory scope enables HYTN to participate in the global supply chain for cannabinoid-based therapeutics through internationally compliant manufacturing and strategic pharmaceutical partnerships.

^{1. _{Jazz Pharmaceuticals. Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024.}}

About HYTN Innovations Inc.

HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.

About Cannabis Drug Licenses (CDL)
A CDL is issued by Health Canada under the Food and Drug Regulations and authorizes the possession, production, packaging, labelling, and distribution of cannabis when used as an active ingredient in pharmaceutical drug products. The CDL is required for any company intending to manufacture prescription drugs containing cannabis for human use. It can only be obtained by holders of a DEL and must meet the same regulatory standards applied to conventional pharmaceutical manufacturers, including compliance with GMP

About Good Manufacturing Practices (GMP)

GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.

Schreibe Deinen Kommentar